•  

Gabapentin Update

Division of Professional Licensing Gabapentin Update

FAQ sheet and updates regarding Gabapentin being a Schedule V controlled substance. 

Controlled Substances Advisory Committee — 2023 Legislative Recommendations

Letter detailing concerns regarding Gabapentin

Copyright © 2024 DOPL Toolkit for Controlled Substances | All rights reserved.

Pain Management

Acute or Opioid Naïve
Chronic/Long Term
Pediatric Pain

Navigating Conversations with Patients

Stigma Reducing Language
Motivational Interviewing
Difficult Conversations

Patient Evaluation/Risk Identification

Tools for Assessing Substance Use Risk
Tools for Assessing Pain
Tools for Screening Mental Health Conditions and Suicide Risk
Contract for Controlled Substances and Suicide Risk

Implementing the CDC Guidelines

Training for the Guide
Guidelines at a Glance
Clinical Practice Guideline Partner Toolkit
Utah Addendum Guidelines

Risk Assessment

Assessing risk and addressing potential harms of opioid use.

CDC Recommendation 8: Risk Assessment and Mitigation
CDC Recommendation 9: Using PDMP/CSD to monitor
CDC Recommendation 10: Toxicology Testing
CDC Recommendation 11: Opioid and benzodiazepines combination
CDC Recommendation 12: Treatment for OUD

Duration

Deciding duration of initial opioid prescription and conducting follow-up.

CDC Recommendation 6: Acute Pain
CDC Recommendation 7: Reevaluating risks and benefits during follow ups

Dosage

Selecting opioids and determining opioid dosages.

CDC Recommendation 3: Selecting type and dosage
CDC Recommendation 4: Opioid naive patients
CDC Recommendation 5: Tapering and changing opioid dosages

Initiating

Determining whether or not to initiate opioids for pain.

CDC Recommendation 1: Determining whether or not to Initiate opioids for pain
CDC Recommendation 2: Nonopioid medications for acute pain